



ctos[®]

November 13 - 16, 2024
Manchester Grand Hyatt San Diego
San Diego, CA

SCHEDULE
AT A GLANCE



2024 ANNUAL MEETING

THANK YOU

The Connective Tissue Oncology Society
greatly appreciates your support of the 2024 Annual Meeting.

PLATINUM SPONSORS



A member of ONO Pharma



Daiichi-Sankyo



GOLD SPONSOR



BRONZE SPONSORS



SPECIAL THANKS TO FRIENDS OF CTOS:

ADVENCHEN PHARMACEUTICALS, LLC

RIGEL PHARMACEUTICALS

NEW BAY PHARMA



Dear Colleagues,

We are delighted to present the annual CTOS meeting in beautiful San Diego. We have created an exciting program that will showcase talks that provide the latest scientific discovery, translational research, and multidisciplinary care for bone and soft tissue sarcomas. We also aim to continue broadening the expertise of CTOS by expanding the disciplines that attend the meeting. So, bring a friend from outside the sarcoma community and invite them to contribute to our field.

This meeting's *theme* is **Addressing Tumor Heterogeneity**. Sarcomas are dynamic systems that change temporally and spatially under therapeutic selection, and we are more than one intervention away from curing many of them. We will have a scientific session devoted to highlighting current efforts and future directions to address inter- and intra-tumoral heterogeneity in sarcoma.

The *Sarcoma of the Year* is **Dedifferentiated Liposarcoma**. These are exciting times in the liposarcoma field, and we will highlight the preclinical, translational, and clinical discoveries advancing the care of this patient population.

Other highlights of this year's program include a *new* **Foundations of Sarcoma Science Symposium (FSSS)** on Wednesday, November 13. This will run concurrently with our usual Wednesday meetings including TARPSWG and Ultra-Rare Sarcomas. The FSSS will end before the SARC meeting. We will also have two lively **Debates** during the meeting focused on approaches to targeting drug resistance and the role of hypofractionated radiation therapy in current practice.

Of course, CTOS is known for multidisciplinary networking so enjoy socializing with colleagues at the **Welcome Reception** on Wednesday evening at the **Malibu Farms Restaurant** overlooking San Diego Bay, interact with presenters during the Poster Reception on Thursday evening, and finally, we will welcome you aboard the **USS Midway** for the **Friday Night Gala!** CTOS will have the entire aircraft carrier for the evening where you can experience different flight simulators, take guided tours of this floating city, as well as enjoy great food, drinks, and dancing!
As a reminder, it is mandatory that you wear closed toe shoes without heels on the USS Midway.

We look forward to seeing you in San Diego this year for another informative and highly collaborative meeting.

Sincerely yours,

Damon Reed, MD,
2024 CTOS President

2024 Program Committee
Ana Sebio, MD
B. Ashleigh Guadagnolo, MD, MPH

Jason Sicklick, MD
Odion Binitie, MD

The first and only FDA-approved targeted therapy for adult patients with progressing desmoid tumors who require systemic treatment

OGSIVEO CAN HELP FREE PATIENTS FROM THE GRIP OF DESMOID TUMORS



Not an actual patient. Individual results may vary.

Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

Important Safety Information

Warnings and Precautions

Diarrhea: Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.

Ovarian Toxicity: Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.

Hepatotoxicity: ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations ($>5 \times$ ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.

Non-Melanoma Skin Cancers: New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.

Electrolyte Abnormalities: Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate <2 mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.

Embryo-Fetal Toxicity: OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at

maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

Adverse Reactions

The most common ($\geq 15\%$) adverse reactions were diarrhea (84%), ovarian toxicity (75% in the 36 females of reproductive potential), rash (68%), nausea (54%), fatigue (54%), stomatitis (39%), headache (30%), abdominal pain (22%), cough (20%), alopecia (19%), upper respiratory tract infection (17%), and dyspnea (16%).

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in $\geq 2\%$ of patients were ovarian toxicity (4%). The most common laboratory abnormalities ($\geq 15\%$) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

Drug Interactions

CYP3A Inhibitors and Inducers: Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.

Gastric Acid Reducing Agents: Avoid concomitant use with proton pump inhibitors and H2 blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

Please [click here](#) for full Prescribing Information.



Learn more and
access resources at
[OGSIVEO.com/hcp](https://ogsiveo.com/hcp)

Ogsiveo[®]
(nirogacestat)
150mg & 100mg tablets

SpringWorks[®]
THERAPEUTICS

© 2024 SpringWorks Therapeutics, Inc. All rights reserved. C_OGS_US_0332 07/24
OGSIVEO is a registered trademark of SpringWorks Therapeutics, Inc.



ctos[®]

2024
BOARD OF DIRECTORS

Damon Reed, MD, President

Silvia Stacchiotti, MD, Vice President

Robin Jones, MD, Secretary

Maureen O'Sullivan, MD, Treasurer

Carol Swallow, MD, PhD, Immediate Past President

Inga-Marie Schaefer, MD (2022-2024)

Herbert Loong, MD (2022-2024)

Chandrajit Raut, MD (2022-2024)

Noah Federman, MD (2022-2024)

Sandra D'Angelo, MD (2023-2025)

Rebecca Gladdy, MD, PhD (2023-2025)

Nadia Hindi, MD (2023-2025)

Torsten Nielsen, MD, PhD (2023-2025)

Ashleigh Guadagnolo, MD (2024-2026)

Sebastian Bauer, MD (2024-2026)

Paul Huang, MD (2024-2026)

Barbara Rapp, Executive Director



Teceletra[®]

afamitresgene autoleucel
suspension for IV infusion

FDA APPROVED

Learn more about TECELRA at our
informative symposium during CTOS.

Speaker: Sandra D'Angelo, M.D.
Thursday, November 14th at 6:30pm
Cityview Room, 32nd Floor

This is a promotional program sponsored by Adaptimmune. The speaker(s) has/have been compensated.



**SCAN TO LEARN MORE
AT [TECELRA.COM](https://www.tecelra.com)**

Please see [full Prescribing Information](#), including Boxed Warning.






ctos[®]

2024 ANNUAL MEETING

NOVEMBER 13 – 16, 2024
SAN DIEGO, CALIFORNIA

SCHEDULE AT A GLANCE

WEDNESDAY, NOVEMBER 13, 2024

7:00 AM – 5:30 PM	Registration	<i>Palm Court Lobby, 2nd Level</i>
8:00 AM – 12:00 PM	TARPSWG	<i>Seaport Ballroom ABC, 2nd Level</i>
8:00 AM – 3:00 PM	Foundational Science of Sarcomas Symposium 	<i>Seaport Ballroom DE, 2nd Level</i>
	Chairs: <i>David G. Kirsch, MD, PhD</i> <i>Jason K. Sicklick, MD, FACS</i>	
1:00 PM – 3:00 PM	Ultra-Rare Sarcoma Meeting	<i>Seaport Ballroom ABC, 2nd Level</i>
2:00 PM – 5:30 PM	Poster Set-Up	<i>Seaport Ballroom EFGH, 2nd Level</i>
3:30 PM – 5:30 PM	SARC Meeting	<i>Seaport Ballroom ABC, 2nd Level</i>
5:30 PM – 7:00 PM	WELCOME RECEPTION	<i>Malibu Farms</i>



THURSDAY, NOVEMBER 14, 2024

6:30 AM – 5:30 PM	Registration	<i>Palm Court Lobby, 2nd Level</i>
7:00 AM – 8:00 AM	Sunrise Mentorship and Coffee	<i>Seaport Ballroom ABCD, 2nd Level</i>
8:00 AM – 8:30 AM	Opening Ceremony	<i>Harbor Ballroom, 2nd Level</i>
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	<i>Balboa, 2nd Level</i>
8:30 AM – 10:00 AM	SESSION 1: Tumor Heterogeneity & Resistance	
	Moderators: <i>Anand G. Patel, MD, PhD</i> <i>Beat W. Schäfer, PhD</i>	
9:00 AM – 12:00 PM	Nursing and Allied Healthcare Professionals	<i>Vista, 32nd Level</i>
10:00 AM – 10:30 AM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>



COMING SOON

DISCOVER WHAT'S
ON THE HORIZON



© 2024 Deciphera Pharmaceuticals. Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are registered trademarks of Deciphera Pharmaceuticals, LLC. ROMVIMZA and the ROMVIMZA logo are trademarks of Deciphera Pharmaceuticals, LLC. All rights reserved. DCPH-P01665 10/24

THURSDAY, NOVEMBER 14, 2024, CONTINUED

10:30 AM – 11:30 AM	SESSION 2: GIST Moderators: <i>Lori Rink, PhD</i> <i>Patrick Schöffski, Prof Dr</i>	<i>Harbor Ballroom, 2nd Level</i>
11:30 AM – 12:15 PM	DEBATE #1: Should We Try to... Prevent Drug Resistance Through Earlier Combination Treatment vs. Steer and Target Drug Resistance When It Develops? Moderator: <i>Mark Dickson, MD</i> Presenters: <i>Sebastian Bauer, MD</i> <i>Margaret von Mehren, MD</i>	<i>Harbor Ballroom, 2nd Level</i>
12:15 PM – 1:15 PM	Lunch	<i>Seaport Ballroom ABCD, 2nd Level</i>
12:15 PM – 1:15 PM	Executive Committee Meeting	<i>Show Office 7, 2nd Level</i>
1:15 PM – 1:45 PM	HERMAN SUIT LECTURE Integration of Advances in Molecular Biology and Genetics in Sarcoma Research as CTOS has Developed Presenter: <i>Irene Andrulis, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
1:45 PM – 3:15 PM	SESSION 3: Bone Sarcomas Moderators: <i>Claudia M. Valverde Morales, MD, PhD</i> <i>Ravin Ratan, MD, MEd</i>	<i>Harbor Ballroom, 2nd Level</i>
3:15 PM – 3:45 PM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>
3:45 PM – 4:45 PM	SESSION 4: Orthopedic Resection & Reconstruction Moderators: <i>Juan P. Zumárraga Montaña, MD, MSc, PhD</i> <i>Rosanna Wustrack, MD</i>	<i>Harbor Ballroom, 2nd Level</i>
4:45 PM – 5:45 PM	SESSION 5: Preclinical Models and Clinical Translation Moderators: <i>Alice Soragni, PhD</i> <i>Elizabeth A. Stewart, MD</i>	<i>Harbor Ballroom, 2nd Level</i>
5:45 PM – 6:45 PM	POSTER RECEPTION	<i>Seaport Ballroom EFGH, 2nd Level</i>
6:30 PM – 8:15 PM	A Joint Effort to Improve Care in Tenosynovial Giant Cell Tumors: Applying a Collaborative Approach Chair: <i>William D. Tap, MD</i> Presenter: <i>Nicholas M. Bernthal, MD</i> <i>Emanuela Palmerini, MD, PhD</i>	<i>Seaport Ballroom AB, 2nd Level</i>
6:30 PM – 8:30 PM	TECELRA® (afamitresgene autoleucel; 'afami-cel') Cell Therapy for Treatment of Eligible Adults* with MAGE-A4+ Advanced Synovial Sarcoma Speaker: <i>Sandra P. D'Angelo, MD</i>	<i>Cityview Room, 32nd Floor</i>

FRIDAY, NOVEMBER 15, 2024

6:30 AM – 5:00 PM	Registration	<i>Palm Court Lobby, 2nd Level</i>
7:00 AM – 8:00 AM	Sunrise Mentorship and Coffee	<i>Seaport Ballroom ABCD, 2nd Level</i>
8:00 AM – 9:00 AM	SESSION 6: Retroperitoneal and Abdominal Sarcomas Moderators: <i>Emily Keung, MD</i> <i>Nicolas Devaud, MD</i>	<i>Harbor Ballroom, 2nd Level</i>
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	<i>Balboa, 2nd Level</i>
9:00 AM – 10:00 AM	SARCOMA OF THE YEAR: Dedifferentiated Liposarcoma Moderators: <i>Roberta Sanfilippo, MD</i> <i>Winan van Houdt, MD, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
10:00 AM – 10:30 AM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>



Making Bold Strides in Cancer

Our pipeline of antibody-drug conjugates has the potential to change medicine by providing targeted delivery across a variety of tumor targets.

See our science at work.



FRIDAY, NOVEMBER 15, 2024, CONTINUED

11:30 AM – 11:15 AM	DEBATE #2: Hypofractionated Regimens Can Be Used as a Standard of Care for Preoperative Radiotherapy for STS without a Phase 3 Trial Moderator: Mark Dickson, MD Presenters: <i>Aisha Miah, PhD (Pro)</i> <i>B. Ashleigh Guadagnolo, MD MPH (Con)</i>	<i>Harbor Ballroom, 2nd Level</i>
11:15 AM – 12:45 PM	SESSION 7: Radiation Oncology Moderators: <i>Angela M. Hong, MBBS, MMed, PhD</i> <i>Lisette Wiltink, MD PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
12:45 PM – 2:00 PM	CTOS Board Meeting	<i>Ocean Beach, 3rd Level</i>
12:45 PM – 2:00 PM	Lunch	<i>Seaport Ballroom ABCD, 2nd Level</i>
1:45 PM – 2:00 PM	POSTER AWARD ANNOUNCEMENT	<i>Harbor Ballroom, 2nd Level</i>
2:00 PM – 3:00 PM	SESSION 8: Basic Science Moderators: <i>Janai Carr-Ascher, MD, PhD</i> <i>Paul Huang, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
3:00 PM – 3:30 PM	NINA AXELRAD LECTURE Sarcoma Immunotherapy: "Just so" Stories Presenter: <i>Robert G. Maki, MD, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
3:30 PM – 4:00 PM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>
4:00 PM – 5:00 PM	SESSION 9: Structural and Functional Omics Moderators: <i>Sandro Pasquali, MD, PhD</i> <i>Zoe Walters, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
6:00 PM – 10:00 PM	Gala at the USS Midway	<i>USS Midway</i>



SATURDAY, NOVEMBER 16, 2024

7:00 AM – 8:00 AM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>
7:00 AM – 5:00 PM	Registration	<i>Palm Court Lobby</i>
8:00 AM – 9:00 AM	SESSION 10: Pediatric, Adolescent & Young Adult Sarcomas Moderators: <i>Viswatej Avutu, MD</i> <i>Sapna Oberoi, MD, MSc</i>	<i>Harbor Ballroom, 2nd Level</i>
8:30 AM – 5:00 PM	Patient Advocacy Lounge (Hosted by SPAGN)	<i>Balboa, 2nd Level</i>
9:00 AM – 10:00 AM	SESSION 11: Trials in Progress/Late Breaking Trials Moderators: <i>Palma Dileo, MD</i> <i>Steven I. Robinson, MBBS</i>	<i>Harbor Ballroom, 2nd Level</i>
10:00 AM – 10:30 AM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>
10:30 AM – 12:00 PM	SESSION 12: Immunology Moderators: <i>Breelyn A. Wilky, MD</i> <i>Ymera Pignochino, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
12:00 PM – 1:00 PM	Lunch	<i>Seaport Ballroom ABCD, 2nd Level</i>

NOW ENROLLING

ChonDRAGON

A Registration-
Enabling Phase 2
Study of Ozekibart
(INBRX-109) in
Unresectable or
Metastatic
Conventional
Chondrosarcoma



Scan to learn more about this trial
and ozekibart (INBRX-109)

ClinicalTrials.gov Identifier: NCT04950075


INHIBRX

1:00 PM – 2:00 PM	SESSION 13: Creative and Inventive Approaches in Sarcoma Research Moderators: <i>John Mullinax, MD</i> <i>Tom Wei-Wu Chen, MD, PhD</i>	<i>Harbor Ballroom, 2nd Level</i>
2:00 PM – 3:00 PM	SESSION 14: Diagnostic Approaches: Pathologic, Radiologic, and Molecular Moderators: <i>Behrang Amini, MD, PhD</i> <i>Robin L. Jones, BSc, MB, BS, MRCP, MD</i>	<i>Harbor Ballroom, 2nd Level</i>
3:00 PM – 3:30 PM	Coffee Break and Posters	<i>Seaport Ballroom EFGH, 2nd Level</i>
3:30 PM – 4:30 PM	SESSION 15: Desmoid Fibromatosis and TGCT Moderators: <i>Samuel Ford, PhD, FRCS</i> <i>Michiel van de Sande, Professor</i>	<i>Harbor Ballroom, 2nd Level</i>
4:30 PM – 5:30 PM	SESSION 16: Health Services Research, Global Health, Advocacy, and Patient-Centered Outcomes Moderators: <i>Dorian Yarih García-Ortega, MD, MSc, PhD, FACS, FSSO</i> <i>Winta T. Mehtsun, MD, MPH</i>	<i>Harbor Ballroom, 2nd Level</i>
5:30 PM – 6:00 PM	CTOS Business Meeting	<i>Harbor Ballroom, 2nd Level</i>
6:00 PM	Adjourn	

A Joint Effort to Improve Care in **Tenosynovial Giant Cell Tumors**

Applying a Collaborative Approach When Integrating Targeted Therapies in Practice

Join us live in person!



CME/MOC/NCPD/AAPA/IPCE-Certified Live Activity

Join us on Thursday, November 14, 2024

6:30–6:45 PM PST: Registration & Dinner

6:45–8:15 PM PST: Symposium

Manchester Grand Hyatt San Diego

Seaport Ballroom AB (Second Level)

[PeerView.com/TGCT24-Live](https://www.peerview.com/TGCT24-Live)



Register Now!



CHAIR & PRESENTER
William D. Tap, MD
Memorial Sloan Kettering
Cancer Center
New York, New York



PRESENTER
Nicholas M. Bernthal, MD, FAOA
David Geffen School of Medicine
at UCLA
Los Angeles, California



PRESENTER
Emanuela Palmerini, MD, PhD
IRCCS Istituto Ortopedico Rizzoli
Bologna University
Bologna, Italy

This CME/MOC/NCPD/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
This activity is supported by independent educational grants from Daiichi Sankyo, Inc., and Deciphera Pharmaceuticals.
This activity has been developed in partnership with TGCT Support, a program of The Life Raft Group.

PeerView
Live

SPAGN's Global Community 2024

Nearly 70 member groups spanning every continent!



Sarcoma Patient Advocacy Global Network

Visit our website to learn more!



www.sarcoma-patients.org

30th
Anniversary



ctos[®]



Save the
Date

2025 ANNUAL MEETING

The Boca Raton
Boca Raton, Florida
November 12–15



ctos[®] |

Bringing together the
world's sarcoma specialists[®]

The Connective Tissue Oncology Society

For more information,
Please visit the CTOS website:
www.ctos.org

P.O. Box 320574 Alexandria, VA 22320
Phone: 301/502-7371 e-mail: ctos@ctos.org

Barbara Rapp, Executive Director